An open-label, multi-center, long-term extension study to evaluate the safety and tolerability of oral tesaglitazar 0.5mg when addded to insulin therapy in patients with type 2 diabetes mellitus (GALLEX 9)
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2010
At a glance
- Drugs Tesaglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms GALLEX-9
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 18 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 18 Nov 2010 Last checked against ClinicalTrials.gov record.